Evolving management of patients treated by drug-eluting stent: Prevention of late events |
| |
Institution: | 1. Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy;2. Interventional Cardiology, S. Eugenio Hospital, Rome, Italy;3. Oxford Heart Centre, The John Radcliffe Hospital, Oxford, United Kingdom |
| |
Abstract: | SummaryDrug eluting stents (DES) were introduced in clinical practice to overcome the problem of in-stent restenosis (ISR) that limited the overall efficacy of percutaneous coronary revascularization with bare metal stent (BMS). Long-term outcome data confirm a sustained benefit of DES as compared with BMS. However, this benefit is mainly evident in the first year of follow-up. Indeed, DES-related events may extend over this time, due to late events (late ISR and/or very late stent thrombosis). Prevention of late failure of DES may become a specific therapeutic target. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|